Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Abstract

BACKGROUND CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis. METHODS This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody. A single cilta-cel infusion (target dose 0·75 × 106 CAR-positive viable T cells per kg) was administered 5-7 days after start of lymphodepletion. The primary endpoints were safety and confirmation of the recommended phase 2 dose (phase 1b), and overall response rate (phase 2) in all patients who received treatment. Key secondary endpoints were duration of response and progression-free survival. This trial is registered with ClinicalTrials.gov, NCT03548207. FINDINGS Between July 16, 2018, and Oct 7, 2019, 113 patients were enrolled. 97 patients (29 in phase 1b and 68 in phase 2) received a cilta-cel infusion at the recommended phase 2 dose of 0·75 × 106 CAR-positive viable T cells per kg. As of the Sept 1, 2020 clinical cutoff…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00933-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 25 references

Cited by

See all 1,756

Metadata

Authors
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T.-M., Allred, A. J., Olyslager, Y., Banerjee, A., Jackson, C. C., Goldberg, J. D., Schecter, J. M., Deraedt, W., Zhuang, S. H., Infante, J., Geng, D., Wu, X., Carrasco-Alfonso, M. J., Akram, M., Hossain, F., Rizvi, S., Fan, F., Lin, Y., Martin, T., & Jagannath, S.
Affiliations
  • Levine Cancer Institute (US)
  • University of Chicago Medical Center (US)
  • UPMC Hillman Cancer Center (US)
  • Abramson Cancer Center (US)
  • University Health Network (CA)
  • Medical College of Wisconsin (US)
  • City Of Hope National Medical Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Wayne State University (US)
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
  • Janssen Research & Development (United States) (US)
  • Janssen (Belgium) (BE)
  • Legend Biotech (United States) (US)
  • Mayo Clinic (US)
  • University of California, San Francisco (US)
Corresponding author
Jagannath, Sundar
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-07
Volume
398
Issue
10297
Pages
314-324
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3176532045
Cited by
1,756
References
25
Citations by year
2026: 283 · 2025: 370 · 2024: 424 · 2023: 355 · 2022: 279 · 2021: 42
FWCI
100.09
Type
journal article
Language
en
Update notices
erratum (2021-10-02)
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Research and Development LLC
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
ciltacabtagene autoleucel, CAR T-cell therapy, BCMA, multiple myeloma, relapsed/refractory multiple myeloma, nanobodies, lymphocyte depletion, overall response rate, progression-free survival, safety, cytokine release syndrome, neurotoxicity, CAR T cell persistence
MeSH terms
Receptors, Chimeric Antigen, Progression-Free Survival, Aged, Female, Humans, Male, Middle Aged, Multiple Myeloma, United States, Immunotherapy, Adoptive, B-Cell Maturation Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00933-8
The paper
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T.-M., Allred, A. J., Olyslager, Y., . . . Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet. https://doi.org/10.1016/s0140-6736(21)00933-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.